You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Ad5 vectored vaccine

Showing 1 - 25 of 8,414
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

COVID-19 Trial in Nanjing (Recombinant SARS-CoV-2 Ad5 vectored vaccine, Inactive SARS-CoV-2 vaccine (Vero cell))

Completed
  • COVID-19
  • Recombinant SARS-CoV-2 Ad5 vectored vaccine
  • Inactive SARS-CoV-2 vaccine (Vero cell)
  • Nanjing, Jiangsu, China
    Jiangsu Provincial Center for Disease Control and Prevention
Mar 28, 2022

COVID-19 Trial in Lianyungang (batch 1 of Ad5-nCoV, batch 2 of Ad5-nCoV, batch 3 of Ad5-nCoV)

Completed
  • COVID-19
  • batch 1 of Ad5-nCoV
  • +2 more
  • Lianyungang, Jiangsu, China
    Guanyun Center for Disease Control and Prevention
Apr 5, 2022

COVID-19 Trial in Nanjing (recombinant Ad5 vectored COVID-19 vaccine, RBD-based protein subunit vaccine (ZF2001) against

Completed
  • COVID-19
  • recombinant Ad5 vectored COVID-19 vaccine
  • +2 more
  • Nanjing, Jiangsu, China
    Jiangsu Provincial Center for Diseases Control and Prevention
Mar 28, 2022

COVID-19 Trial in Wuhan (Ad5-nCoV)

Unknown status
  • COVID-19
  • Ad5-nCoV
  • Wuhan, Hubei, China
    Zhongnan Hospital
Dec 3, 2020

COVID-19 Trial in Nanjing (Ad5-nCoV-IH, Ad5-nCoV-IM, CoronaVac)

Active, not recruiting
  • COVID-19
  • Ad5-nCoV-IH
  • +2 more
  • Nanjing, Jiangsu, China
    Jiangsu Provincial Center for Diseases Control and Prevention
Aug 12, 2022

Immunogenicity and Safety of a Recombinant Adenovirus Type-5-vectored COVID-19 Vaccine Using for Sequential Immunization Trial

Recruiting
  • Immunogenicity and Safety of a Recombinant Adenovirus Type-5-vectored COVID-19 Vaccine Using for Sequential Immunization
  • Recombinant adenovirus type-5-vectored COVID-19 vaccine
  • Hangzhou, Zhejiang, China
    Xihu District Center for Disease Control and Prevention
May 12, 2022

Adenovirus Type-5 Vectored COVID-19 Vaccine Trial in Wuhan (Adenovirus Type-5 Vectored COVID-19 Vaccine)

Completed
  • Adenovirus Type-5 Vectored COVID-19 Vaccine
  • Adenovirus Type-5 Vectored COVID-19 Vaccine
  • Wuhan, Hubei, China
    A rehabilitation centre in Wuhan
Mar 28, 2022

Respiratory Syncytial Virus Infections Trial in Cincinnati (PIV5-vectored RSV Vaccine (BLB-201) Low Dose, PIV5-vectored RSV

Not yet recruiting
  • Respiratory Syncytial Virus Infections
  • PIV5-vectored RSV Vaccine (BLB-201) Low Dose
  • +2 more
  • Cincinnati, Ohio
    Cincinnati Children's Hospital Medical Center
Dec 20, 2022

COVID-19 Trial (Bivalent Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector), Bivalent Recombinant COVID-19 Vaccine

Not yet recruiting
  • COVID-19
  • Bivalent Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector)
  • +2 more
  • (no location specified)
Jul 5, 2022

Human Papillomavirus Infections Trial in Belgium, United States (Ad26.HPV16, Ad26.HPV18, MVA.HPV16/18)

Terminated
Has Results
  • Human Papillomavirus Infections
  • Ad26.HPV16
  • +3 more
  • Doral, Florida
  • +11 more
Nov 23, 2021

COVID-19 Trial in Yancheng (Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) 0.5ml, Recombinant Novel

Active, not recruiting
  • COVID-19
  • Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) 0.5ml
  • Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) 0.3ml
  • Yancheng, Jiangsu, China
    Funing Center for Disease Control and Prevention
Oct 28, 2022

Bird Flu, Influenza Trial in United States (Placebo, Ad4-H5-Vtn, Sanofi Pasteur Influenza Virus Vaccine, H5N1)

Completed
  • Bird Flu
  • Influenza
  • Placebo
  • +2 more
  • Lexington, Kentucky
  • +3 more
Mar 16, 2020

COVID-19 Trial (1 Nebulized inhalation for booster groups, 2 Nebulized inhalation for booster groups, 3 Nebulized inhalation for

Recruiting
  • COVID-19
  • 1 Nebulized inhalation for booster groups
  • +23 more
  • Xiangxi, Hunan, China
    CDC of of Luxi County, Xiangxi Tujia and Miao Autonomous Prefect
Oct 24, 2022

COVID-19 Trial in Nanjing (Intramuscularly administered Ad5-nCoV vaccine, Aerosolized Ad5-nCoV, DelNS1-2019-nCoV-RBD-OPT1)

Not yet recruiting
  • COVID-19
  • Intramuscularly administered Ad5-nCoV vaccine
  • +3 more
  • Nanjing, Jiangsu, China
    Jiangsu Provincial Center for Disease Control and Prevention
May 10, 2023

COVID-19 Trial (Recombinant COVID-19 vaccine (adenovirus type 5 vector) for Inhalation (Ad5-nCoV-IH), Placebo)

Not yet recruiting
  • COVID-19
  • Recombinant COVID-19 vaccine (adenovirus type 5 vector) for Inhalation (Ad5-nCoV-IH)
  • Placebo
  • (no location specified)
Nov 19, 2021

COVID-19 Trial in Taizhou (Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector), Recombinant Novel Coronavirus

Completed
  • COVID-19
  • Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
  • Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) -placebo
  • Taizhou, Jiangsu, China
    Taixing City center for Disease Control and Prevention
Oct 28, 2022

COVID-19 Vaccine Trial in Ciudad autónoma de Buenos Aires, Ciudad Autonoma de Buenos Aire, Ciudad Autónoma de Buenos Aires

Active, not recruiting
  • COVID-19 Vaccine
  • Ad5-nCov
  • Ciudad autónoma de Buenos Aires, Buenos Aires, Argentina
  • +2 more
Sep 28, 2022

SARS-CoV-2 Infection Trial in Bangkok (Full dose of Ad26.COV2. 5x10^10vp, Half dose of Ad26.COV2. 2.5x10^10vp)

Recruiting
  • SARS-CoV-2 Infection
  • Full dose of Ad26.COV2. 5x10^10vp
  • Half dose of Ad26.COV2. 2.5x10^10vp
  • Bangkok, Thailand
    Vaccine Trial Centre, Faculty of Tropical Medicine, Mahidol Univ
Sep 11, 2022

Norovirus Infections Trial in Cypress, New Orleans, Austin (VXA-GI.1.NN, Placebo Tablet)

Completed
  • Norovirus Infections
  • VXA-GI.1.NN
  • Placebo Tablet
  • Cypress, California
  • +2 more
Sep 19, 2022

COVID-19 Trial in Wuhan (Prototype and Omicron BA.4/5 Bivalent Recombinant COVID-19 Vaccine(Adenovirus Type 5 Vector) For

Recruiting
  • COVID-19
  • Prototype and Omicron BA.4/5 Bivalent Recombinant COVID-19 Vaccine(Adenovirus Type 5 Vector) For Inhalation
  • +2 more
  • Wuhan, Hubei, China
    Zhongnan Hospital of Wuhan University
Jun 1, 2023

COVID-19 Trial (Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector), Recombinant COVID-19 vaccine (adenovirus type

Not yet recruiting
  • COVID-19
  • Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
  • Recombinant COVID-19 vaccine (adenovirus type 5 vector) for Inhalation (Ad5-nCoV-IH)
  • (no location specified)
Jan 11, 2022

Plasmodium Falciparum Trial run by the (NMRC-M3V-Ad-PfCA, NMRC-MV-Ad-PfC, NMRC-M3V-Ad-PfCA)

Completed
Has Results
  • Plasmodium Falciparum
  • NMRC-M3V-Ad-PfCA
  • NMRC-MV-Ad-PfC, NMRC-M3V-Ad-PfCA
  • Bethesda, Maryland
    Naval Medical Research Center (NMRC) Clinical Trials Center
Apr 28, 2021

HPV Infection, CIN1 Trial in Belgium, Estonia, United Kingdom (ChAdOx1-HPV, MVA-HPV, Placebo)

Active, not recruiting
  • HPV Infection
  • CIN1
  • ChAdOx1-HPV
  • +2 more
  • Antwerp, Belgium
  • +15 more
Jan 9, 2023

Norovirus Infections Trial in Cypress (VXA-G1.1-NN)

Completed
  • Norovirus Infections
  • VXA-G1.1-NN
  • Cypress, California
    WCCT Global, Inc.
Sep 19, 2022

Tuberculosis Trial in Hamilton (Ad5Ag85A)

Completed
  • Tuberculosis
  • Ad5Ag85A
  • Hamilton, Ontario, Canada
    McMaster University Medical Centre
Oct 25, 2021